Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06464952 · ClinicalTrials.gov registry record · NA
Microbiome Modulation With Prebiotics in PTSD and Cirrhosis
A NA study of PTSD and Cirrhosis, sponsored by Hunter Holmes Mcguire Veteran Affairs Medical Center.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06464952: Recruiting NA study of PTSD and Cirrhosis, sponsored by Hunter Holmes Mcguire Veteran Affairs Medical Center.
NCT06464952 is a NA study of PTSD and Cirrhosis that is actively recruiting participants, run by Hunter Holmes Mcguire Veteran Affairs Medical Center. The registered enrollment target is 30 participants, below the 302-participant average among 154 other PTSD trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06464952, a NA study of PTSD and Cirrhosis, is actively recruiting participants, sponsored by Hunter Holmes Mcguire Veteran Affairs Medical Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Despite medical advancements, PTSD remains a major issue in Veterans1. Current treatment strategies have relatively poor adherence. In patients with PTSD and cirrhosis, there is greater cognitive impairment as well as changes in gut microbiome structure and function2,3. In addition, when there is concomitant cirrhosis, medication-related treatment options become even narrower from a safety and tolerability perspective and cognitive issues pertaining to cirrhosis could impact participation3. Changes in gut microbiome in Veterans with cirrhosis and PTSD compared to those with cirrhosis without PTSD is characterized by a greater relative expression of pathobionts and reduction in stool microbiome diversity with reduction in bacteria that produce beneficial short chain fatty acids (SCFA)2. Modulation of the gut microbiome in patients with cirrhosis and PTSD may be an important therapeutic target. In prior studies with cirrhosis alone, microbial modulation using diet, antibiotics such as rifaximin, probiotics, and fecal microbiota transplant have improved gut microbial diversity and clinical outcomes in some cases4,5. In patients with cirrhosis without PTSD and in patients with PTSD without cirrhosis there is emerging evidence regarding prebiotics and other forms of gut microbial modulation. Prebiotics are such an example6. Prebiotics are natural fibers derived from carbohydrates and can be beneficial to gut microbiota (good bacteria in the gut)6. Resistant starches (RS) are dietary fiber prebiotics found naturally in many foods including potatoes, plantains, and legumes6,7. In addition to being highly accessible, RS have been shown to be well tolerated with few adverse reactions. While no studies of RS exist in PTSD + cirrhosis patients, a meta-analysis of RS in IBD has shown RS to be an effective treatment in both animal and clinical studies where improvements in clinical remission and reduced mucosal damage were found7. However, there is insufficient data regarding p
Primary Outcome
Shannon diversity at end of interventions between both groups
Interventions
- DIETARY_SUPPLEMENT Resistant potato starch
- DIETARY_SUPPLEMENT Powdered cellulose
Study Locations (1)
Virginia
- Hunter Holmes McGuire VA Medical Center - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-07-31 |
| Est. Completion | 2025-09-25 |
| Phase | NA |
What NCT06464952 shows while recruiting
NCT06464952 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 302-participant average among 154 other PTSD trials with a reported enrollment target (90% lower).
The record links to 2 conditions, with PTSD appearing as the primary indexed condition, and to 2 interventions - of which Resistant potato starch is the first listed.
NCT06464952 reports a single indexed study location in Virginia.
Frequently Asked Questions
What is clinical trial NCT06464952 about?
NCT06464952 is a clinical study titled "Microbiome Modulation With Prebiotics in PTSD and Cirrhosis". Despite medical advancements, PTSD remains a major issue in Veterans1. Current treatment strategies have relatively poor adherence. In patients with PTSD and cirrhosis, there is greater cognitive impairment as well as changes in gut microbiome structure and function2,3. In addition, when there is co...
What is the current status of trial NCT06464952?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2024-07-31. Estimated completion is 2025-09-25.
What conditions does trial NCT06464952 study?
This clinical trial studies the following conditions: PTSD, Cirrhosis.
What interventions are being tested in trial NCT06464952?
The interventions under investigation include: Resistant potato starch (DIETARY_SUPPLEMENT), Powdered cellulose (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06464952?
This trial is sponsored by Hunter Holmes Mcguire Veteran Affairs Medical Center, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06464952 being conducted?
This trial has 1 study location across Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for PTSD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06464952's enrollment target sits among peer trials
30 122nd of 154 higher than 25 of 154 other PTSD trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other PTSD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Testing an Integrated PTSD and Weight Management Intervention: A Hybrid Type 1 Trial
RECRUITING · NA
-
Treatments for Insomnia in Veterans With PTSD
RECRUITING · NA
-
REstoring Mental Health Through COmmUnity-based Psychological Services in New York City
RECRUITING · NA
-
Recovery Through Inhibitory Learning, Self-Efficacy Building, Problem Solving, and Community Building
RECRUITING · NA
-
Project Safe Guard-Trauma
RECRUITING · NA
-
Neuromodulation of the Fear Extinction Circuit Using Temporally and Anatomically Specific TMS in Humans
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI